S1613
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- NCT03365882 ↗
- Completed
- SWOG Cancer Research Network
- Focused
We haven't built an HCP commentary report on S1613 (trastuzumab plus pertuzumab in RAS/BRAF wild-type, HER2-positive metastatic colorectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1613 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7
- Interventions
- Cetuximab; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Pertuzumab; Trastuzumab; HER-2 testing
- Arms
- Arm I (pertuzumab, trastuzumab) · Experimental
- Arm II (cetuximab, irinotecan hydrochloride) · Experimental
- Enrollment
- 240
- Primary outcomes
- Progression-free Survival(PFS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Nov 27, 2017
- Primary completion
- Nov 1, 2022
- Results posted
- Yes
- Registry record
- NCT03365882 · updated Feb 10, 2026
Publications
linked from the registry- Raghav KPS, Guthrie KA, Tan B Jr, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, Esparaz BT, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean EG, Kopetz S, Hochster HS, Philip PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. J Clin Oncol. 2025 Apr 10;43(11):1348-1357. doi: 10.1200/JCO-24-01710. Epub 2025 Jan 6. PubMed 39761503